ODA
E642116
ODA refers to the Orphan Drug Act of 1983, a U.S. law that incentivizes the development of treatments for rare diseases by offering benefits such as market exclusivity and tax credits to drug manufacturers.
All labels observed (1)
| Label | Occurrences |
|---|---|
| ODA canonical | 3 |
How this entity was disambiguated
This entity first appeared as the object of triple T7110891 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ODA Context triple: [Orphan Drug Act of 1983, alsoKnownAs, ODA]
-
A.
OVDAS
OVDAS is a Chilean volcanic monitoring and surveillance agency responsible for observing and assessing volcanic activity across the country.
-
B.
ODI
ODI is the commonly used abbreviation for the Open Data Institute, a UK-based organization that advocates for and supports the use of open data to drive innovation and social impact.
-
C.
ODI
ODI (One Day International) is a limited-overs format of cricket in which each team typically faces a fixed number of overs, usually 50, and matches are completed in a single day.
-
D.
ODI
ODI is a comprehensive data integration platform by Oracle used for high-performance data movement, transformation, and loading across heterogeneous systems.
-
E.
ODAM
ODAM is an organizational unit within the U.S. Department of Defense responsible for overseeing administrative, management, and support functions for the Office of the Secretary of Defense.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: ODA Target entity description: ODA refers to the Orphan Drug Act of 1983, a U.S. law that incentivizes the development of treatments for rare diseases by offering benefits such as market exclusivity and tax credits to drug manufacturers.
-
A.
OVDAS
OVDAS is a Chilean volcanic monitoring and surveillance agency responsible for observing and assessing volcanic activity across the country.
-
B.
ODI
ODI is the commonly used abbreviation for the Open Data Institute, a UK-based organization that advocates for and supports the use of open data to drive innovation and social impact.
-
C.
ODI
ODI (One Day International) is a limited-overs format of cricket in which each team typically faces a fixed number of overs, usually 50, and matches are completed in a single day.
-
D.
ODI
ODI is a comprehensive data integration platform by Oracle used for high-performance data movement, transformation, and loading across heterogeneous systems.
-
E.
ODAM
ODAM is an organizational unit within the U.S. Department of Defense responsible for overseeing administrative, management, and support functions for the Office of the Secretary of Defense.
- F. None of above. chosen
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf | United States federal law ⓘ |
| administeredBy |
FDA Office of Orphan Products Development
ⓘ
linked to:
Office of Orphan Products Development
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| aimsTo | incentivize development of orphan drugs ⓘ |
| appliesTo |
biologics
ⓘ
drugs ⓘ rare diseases ⓘ |
| beneficiary |
biotechnology companies
ⓘ
drug manufacturers ⓘ patients with rare diseases ⓘ |
| country |
United States
ⓘ
linked to:
United States of America
|
| definesConcept |
orphan drug
ⓘ
rare disease ⓘ |
| enactedBy | United States Congress ⓘ |
| encourages | research and development for rare conditions ⓘ |
| focusesOn | unmet medical needs in small patient populations ⓘ |
| hasAbbreviation | ODA ⓘ |
| hasEffect |
increases number of approved treatments for rare diseases
ⓘ
reduces financial risk of orphan drug development ⓘ |
| hasProvision |
clinical research tax credit
ⓘ
market exclusivity period for designated drugs ⓘ orphan drug designation process ⓘ user fee exemptions for designated products ⓘ |
| influenced | orphan drug legislation in other countries ⓘ |
| jurisdiction |
United States federal government
ⓘ
linked to:
United States government
|
| language | English ⓘ |
| legalStatus | in force ⓘ |
| policyGoal |
improve access to treatments for rare diseases
ⓘ
stimulate private investment in orphan drug development ⓘ |
| providesIncentive |
fee waivers
ⓘ
grant funding ⓘ market exclusivity ⓘ tax credits ⓘ |
| purpose | to encourage development of drugs for rare diseases ⓘ |
| regulates | orphan drugs ⓘ |
| relatedTo |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
rare disease advocacy groups ⓘ |
| sector |
healthcare
ⓘ
pharmaceutical industry ⓘ |
| shortName | ODA ⓘ |
| signedBy | Ronald Reagan ⓘ |
| subjectArea |
health law
ⓘ
pharmaceutical regulation ⓘ rare disease policy ⓘ |
| typeOfIncentiveLaw | innovation incentive law ⓘ |
| yearEnacted | 1983 ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: ODA Description of subject: ODA refers to the Orphan Drug Act of 1983, a U.S. law that incentivizes the development of treatments for rare diseases by offering benefits such as market exclusivity and tax credits to drug manufacturers.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject linked to:
ODA